Compositions and methods for controlled delivery of inhibitory ribonucleic acids
Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nanoparticles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time. Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation. Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided.
1. A composition for intracellular delivery of inhibitory polynucleotides consisting essentially of
polymeric nanoparticles, and
inhibitory polynucleotides complexed to a polyamine polycation in a molar ratio of the polycation nitrogen (“N”) to the polynucleotide phosphate (“P”) of between approximately 8:1 and 15:1,
wherein the nanoparticles are prepared by first forming the polynucleotide-polycation complex in the absence of the polymer of the nanoparticle and subsequently contacting the polynucleotide-polycation complex with the polymer to form nanoparticles encapsulating the polynucleotide-polycation complex,
wherein the polynucleotide-polycation complex encapsulated nanoparticles are formed by a double-emulsion technique comprising (i) adding an aqueous solution comprising the polynucleotide-polycation complexes to a polymer solution comprising the polymer dissolved in an organic solvent to form a first emulsion; (ii) adding the first emulsion to a first surfactant solution followed by mixing to form a second emulsion; (iii) adding the second emulsion to a second surfactant solution; and (iv) removing the organic solvent to yield polynucleotide-polycation complex encapsulated nanoparticles.
2. The composition of claim 1 , wherein the inhibitory polynucleotide is an inhibitory RNA selected from the group consisting of siRNA, shRNA, miRNA, piRNA, external guide sequences (EGS), and ribozymes.
3. The composition of claim 2 , wherein the inhibitory RNA is a double-stranded RNA.
4. The composition of claim 1 , wherein the polycation is a polyamine selected from the group consisting of spermine, spermidine, cadaverine and putrescine.
5. The composition of claim 4 , wherein the nanoparticles are formed of a polymer having targeting or binding molecules attached thereto or therein.
6. The composition of claim 1 , wherein the polymeric nanoparticles are between 50 and 500 nanometers in diameter.
7. The composition of claim 2 , wherein the inhibitory RNA targets an mRNA encoded by an oncogene or a viral gene.
8. The composition of claim 1 , wherein the polycation increases the encapsulation efficiency of the inhibitory polynucleotide by at least 4-fold as compared to the encapsulation efficiency of inhibitory polynucleotide in the absence of the polycation.
9. The composition of claim 1 , wherein the polymer is PLGA.
10. The composition of claim 2 , wherein the nanoparticles release an effective amount of inhibitory RNA to cause a reduction of at least 10% of the expression of the mRNA that is targeted by the inhibitory nucleic acid over a period of a week.
11. The composition of claim 1 further comprising functional elements bound to or incorporated into the surface of the nanoparticles,
wherein the functional elements are selected from the group consisting of targeting molecules, protein transduction domains and fusogenic peptides.
12. The composition of claim 11 , wherein the functional agents are bound to the nanoparticles by coupling agents.
13. The composition of claim 12 , wherein the coupling agents are bound to the functional elements by the non-covalent interaction of affinity tags conjugated to the coupling agents and complementary affinity tags conjugated to the functional elements.
14. A method for increasing the encapsulation efficiency of polynucleotides into polymeric particles comprising contacting inhibitory polynucleotides with a polyamine polycation in a molar ratio of the polycation nitrogen (“N”) to the polynucleotide phosphate (“P”) of between approximately 8:1 and 15:1 to form a polynucleotide-polycation complex and encapsulating the complex within polymeric nanoparticles,
wherein the nanoparticles are prepared by first forming the polynucleotide-polycation complex in the absence of the polymer of the nanoparticle and subsequently contacting the polynucleotide-polycation complex with the polymer,
wherein the polynucleotide-polycation complex encapsulated nanoparticles are formed by a double-emulsion technique comprising (i) adding an aqueous solution comprising the polynucleotide-polycation complexes to a polymer solution comprising the polymer dissolved in an organic solvent to form a first emulsion; (ii) adding the first emulsion to a first surfactant solution followed by mixing to form a second emulsion; (iii) adding the second emulsion to a second surfactant solution; and (iv) removing the organic solvent to yield polynucleotide-polycation complex encapsulated nanoparticles.
15. The method of claim 14 , wherein the polycation is a polyamine selected from the group consisting of spermine, spermidine, cadaverine and putrescine.
16. The method of claim 14 , wherein the polyamine is spermidine.
17. A method of reducing the expression of an mRNA in a cell comprising administering the composition of claim 2 to cells or an animal in need thereof.
18. The composition of claim 1 , wherein the polymer forming the nanoparticles is a synthetic polymer.
19. The composition of claim 1 , wherein the N:P ratio is approximately 8:1.
20. The composition of claim 1 , wherein the inhibitory polynucleotide is an siRNA, wherein the polyamine polycation is spermine, spermidine, cadaverine, or putrescine, and wherein the molar ratio of the polycation nitrogen (“N”) to the polynucleotide phosphate (“P”) is approximately 8:1.
21. The composition of claim 20 , wherein the inhibitory RNA inhibits viral infection, cell entry, or life cycle.
22. The composition of claim 1 , wherein the polynucleotide-polycation complex is formed in an aqueous solution in the absence of the polymer of the nanoparticle and wherein the aqueous solution comprising the polynucleotide-polycation complex is subsequently contacted with the polymer.